Roche acquired rights to glucagon-like-peptide-1 (GLP-1) receptor agonist BIM51077 for treating Type II diabetes and other GLP-1 analogues from Ipsen. Aspreva Pharmaceuticals acquired exclusive worldwide rights from Roche to develop and commercialize Roche’s immunosuppressant, CellCept® and expand its use into autoimmune disease applications.